CVS Health outlines strategy to streamline insurance and cut patient costs | iPharmaCenter

CVS Health has laid out a broad strategy to simplify how Americans use health insurance while tackling the rising cost of care and medicines. The company stated that it is focused on easing administrative burdens for clinicians, shifting payments toward value, and expanding the use of lower‑cost treatment options.

Making utilization management less burdensome

Aetna, the health insurance arm of CVS Health, reports that it now applies prior authorization requirements to fewer medical services than most national competitors. The insurer says it can turn around the large majority of prior authorization requests within a day, and that most electronic submissions are now resolved in real time at the point of request.

The company is also aligning clinical and technology criteria with other major plans so that common services follow the same rules when patients move between insurers. For high‑volume services that account for a substantial share of prior authorization traffic, cross‑payer standards are being adopted to reduce repeated documentation and confusion for providers.

Aetna has started to re‑design prior authorization. For conditions such as cancer and musculoskeletal disease, a single request can cover a sequence of tests, interventions, and supportive therapies that historically would have required multiple separate authorizations.

The insurer is also embedding clinical staff inside large health systems to support discharge planning and follow‑up, aiming to lower readmissions and shorten avoidable hospital stays. CVS Health expects these collaborations to translate into measurable improvements in acute‑care outcomes and cost trends over time.

Linking payment to better outcomes

CVS Health is continuing to move Medicare spending into arrangements where providers are rewarded for keeping patients well rather than only being paid per service. The organisation reports that most of its Medicare outlays now flow through value‑oriented contracts, which it associates with lower costs, better safety, and higher satisfaction.

Regulators have given these Medicare Advantage offerings strong marks in quality programs that track clinical performance and member experience. CVS Health positions these ratings as evidence that tighter alignment between incentives and outcomes can benefit patients and payers simultaneously.

Expanding use of lower‑cost medicines

On the pharmacy side, CVS Health is using its scale to push uptake of biosimilars and other alternatives to expensive originator biologics. For example, the company reports that a biosimilar strategy in the autoimmune segment has already generated over a billion dollars in savings for plan sponsors. Stelara biosimilars are introduced at a price 86% lower than the original drug.

The company is also passing negotiated concessions on drugs more directly to patients at the point of sale. A growing share of members now receive the benefit of rebates at the pharmacy counter, and CVS Health’s pharmacy benefit manager has created pricing options designed to make these flows more transparent for employer and health‑plan clients.